Optic neuritis after infliximab therapy

Faillace, César; Almeida, João Ricardo Maltez de; Carvalho, Jozélio Freire de

doi:10.1007/s00296-011-2316-x

Cited by 24 publications

(9 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Besides the effect of anti-TNFa therapy on definite MS, a relation between anti-TNFa agents and newly onset of MS or MS-like syndromes has been documented [13–26, 35–38]. It is unclear, however, whether these demyelinating events are coincidental or whether they are causally associated with the use of TNFa antagonists.…”

Section: Discussionmentioning

confidence: 99%

Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature

Andreadou

Kemanetzoglou

Brokalaki

et al. 2013

Case Reports in Neurological Medicine

View full text Add to dashboard Cite

Tumor necrosis factor antagonists (anti-TNFa) are an established therapeutic option for several autoimmune and inflammatory bowel diseases. Despite their clinical effectiveness, neurological adverse events have been reported and literature data suggest a potential role of anti-TNFa in the induction of demyelination of the CNS. We present four patients treated with anti-TNFa who developed symptoms suggestive of CNS demyelination. The first patient, a 17-year-old male who received etanercept for psoriatic arthritis for eight months, presented with dysesthesias up to T4 level. The second patient, a 30-year-old male treated with adalimumab for three years due to ankylosing spondylitis, presented with right unilateral tinnitus. The third case, a 47-year-old female, received etanercept for four years because of psoriatic arthritis and developed persistent headache and left-sided face and head numbness. Finally, the fourth patient, a 57-years-old female treated with etanercept for six years due to ankylosing spondylitis, presented with difficulty in speech, swallowing, and ptosis of the right corner of the mouth. In all cases, brain MRI showed lesions suggestive of demyelination, while positive oligoclonal bands were detected in the CSF. Anti-TNFa treatments were discontinued and patients showed clinical improvement with pulsed intravenous corticosteroid therapy. CNS demyelination following anti-TNFa treatment represents a relatively rare but potential serious complication. Close follow-up and MRI monitoring of these patients is mandatory to elucidate whether the clinical manifestations represent adverse events occurring during anti-TNFa therapy or a first demyelinating episode.

show abstract

Section: Discussionmentioning

confidence: 99%

Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature

Andreadou

Kemanetzoglou

Brokalaki

et al. 2013

Case Reports in Neurological Medicine

View full text Add to dashboard Cite

show abstract

“…Patients with RA may present with isolated cranial nerve involvement [65][66][67]. One of the most common cranial nerve dysfunction is optic neuritis, that can be secondary to medical treatment for RA, such as infliximab and etanercept, generally with some improvement of the visual function after withdrawal the drug [65,68]. Demyelination after anti-TNF drugs can develop mostly from 1 week to 12 months after starting the agents, but delay presentations are also described, requiring continuous monitoring [65,69].…”

Section: Central Nervous Systemmentioning

confidence: 97%

Neuropsychiatric manifestations in rheumatoid arthritis

Joaquim

Appenzeller

2015

Autoimmunity Reviews

View full text Add to dashboard Cite

“…Среди очень редких осложнений описывались неврит зрительного нерва [43], саркоидоз [44], дерматомиозит [45] и перикардит [46].…”

Section: оригинальные исследованияunclassified

Adverse Events of Infliximab: From Publication Analysis to Original Studies

ARONOVA¹,

Lukina²,

Sigidin³

2019

BCCM

View full text Add to dashboard Cite

Широкий спектр высокоэффективных генно-инженерных биологических препаратов, введенных в клиническую ревматологию за последние годы, обусловливает особый интерес к их переносимости. Цель-оценка переносимости терапии инфликсимабом у больных ревматоидным артритом. Материал и методы. В статье представлен обзор зарубежной литературы, посвященной изучению нежелательных явлений, возникающих на фоне лечения инфликсимабом, представляющим собой химерное моноклональное антитело к ФНОα. Представлены собственные данные авторов, проанализировавших нежелательные эффекты инфликсимаба у 135 больных ревматоидным артритом в реальной клинической практике. Результаты и их обсуждение. Общая переносимость инфликсимаба была удовлетворительной. Нежелательные явления отмечались в 28,1% случаев. Относительно частыми нежелательными явлениями были инфузионные реакции (снижение артериального давления на 10-20 мм рт.ст. от исходного, тахикардия, ощущение жара), наблюдавшиеся в процессе введения препарата у 15 пациентов (11,1% случаев). У 19 пациентов (14,1%) наблюдались серьезные побочные эффекты, потребовавшие отмены препарата. Среди серьезных нежелательных явлений наиболее часто встречались аллергические реакции (6%) и инфекционные осложнения (5,2%). Наилучшая переносимость отмечалась при лечении комбинацией инфликсимаба и метотрексата. Выводы. В большинстве случаев инфликсимаб безопасен для применения в реальной клинической практике. Перед назначением терапии следует информировать пациентов о риске возникновения нежелательных эффектов, а также перед каждым введением инфликсимаба необходим осмотр ревматологом. Ключевые слова: биологическая терапия, генно-инженерные биологические препараты, инфликсимаб, ингибиторы ФНОα, неблагоприятные реакции, ревматоидный артрит.

show abstract

Optic neuritis after infliximab therapy

Cited by 24 publications

References 18 publications

Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature

Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature

Neuropsychiatric manifestations in rheumatoid arthritis

Adverse Events of Infliximab: From Publication Analysis to Original Studies

Contact Info

Product

Resources

About